Arylamide Compounds Broad-Spectrum Antiviral Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a pressing need for effective and safe therapies to treat or prevent viral infections, particularly against emerging infectious viruses like SARS-CoV-2, as current treatments face challenges with resistance and limited broad-spectrum efficacy.
Innovation Solution
Administration of a therapeutically effective amount of a compound of Formula I, or its pharmaceutically acceptable salt, which is an arylamide compound, to treat or prevent viral infections, potentially combined with antiviral agents such as remdesivir or vaccines, to address the viral infection mechanisms and enhance treatment outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current antiviral treatments are used, then specific viral infections can be treated, but resistance develops and broad-spectrum efficacy is limited
Solution Approach 1:
The patent applies universality by designing brilacidin and its arylamide derivatives as a broad-spectrum antiviral agent that can inhibit multiple different viruses (enveloped and non-enveloped) through a single mechanism of action. The compound targets conserved viral entry mechanisms rather than virus-specific targets, enabling one compound to address multiple viral threats and reduce the need for virus-specific treatments.
Solution Approach 2:
The patent employs an intermediary approach by using brilacidin as a host-directed antiviral that targets host cell factors involved in viral entry and replication rather than directly targeting viral components. This intermediary strategy of modulating host pathways provides broad-spectrum protection while reducing selective pressure for viral resistance, as the host factors are under stronger evolutionary constraint.
2Adaptability or versatility
If new antiviral therapies are developed, then treatment options increase, but safety profiles need to be established
Solution Approach 1:
The patent applies preliminary action by conducting extensive preclinical and clinical safety evaluation of brilacidin before developing its arylamide derivatives. Brilacidin has already completed multiple clinical trials demonstrating safety and efficacy in humans. This preliminary safety data serves as a foundation for the new compounds, allowing faster development while maintaining safety standards, as the arylamide derivatives are designed to retain the favorable safety profile of the parent compound.
3Reliability
If combination therapy is used, then treatment efficacy is enhanced, but treatment complexity increases
Solution Approach 1:
The patent applies merging by formulating brilacidin and its arylamide derivatives as combination therapies that integrate multiple antiviral mechanisms into a single treatment regimen. The compounds can be combined with existing antivirals, vaccines, or immunomodulators to create synergistic effects. This merging approach enhances efficacy while managing complexity through coordinated multi-target intervention rather than separate sequential treatments.
Data Source
AI summary
The present disclosure provides methods for treating or preventing a viral infection with one or more arylamide compounds, or pharmaceutically acceptable salts thereof, or compositions comprising the same, and pharmaceutical compositions comprising one or more arylamide compounds and at least one antiviral agent.